References:
1. Koch C, Li L, Duncan A, Mihaljevic T, Cosgrove D, Loop F. Morbidity
and mortality risk associated with red blood cell and blood- component
transfusion in isolated coronary artery bypass grafting. Crit Care
Med . 2006;34(6):1608-1616.
2. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ.
Effect of Blood Transfusion on Long-Term Survival After Cardiac
Operation. Ann Thorac Surg . 2002;74(4):1180-1186.
3. Brevig J, Mcdonald J, Zelinka ES, Gallagher T, Jin R, Grunkemeier GL.
Blood Transfusion Reduction in Cardiac Surgery: Multidisciplinary
Approach at a Community Hospital. Ann Thorac Surg .
2009;87(2):532-539.
4. Mcgill N, O’Shaughnessy D, Pickering R, Herbertson M, Gill R.
Mechanical methods of reducing blood transfusion in cardiac surgery:
randomised controlled trial. BMJ . 2002;324(7349):1299.
5. Vivacqua A, Koch CG, Yousuf AM, Nowicki ER, Houghtaling PL,
Blackstone EH, et al. Morbidity of Bleeding After Cardiac Surgery : Is
It Blood Transfusion , Reoperation for Bleeding , or Both? Ann
Thorac Surg . 2011;91(6):1780-1790.
6. Biancari F, Mikkola R, Heikkinen J, Lahtinen J, Airaksinen KEJ,
Juvonen T. Estimating the risk of complications related to
re-exploration for bleeding after adult cardiac surgery : a systematic
review and meta-analysis. Eur J Cardiothorac Surg .
2012;41(1):50-55.
7. Stone GW, Clayton TC, Mehran R, Dangas G, Parise H, Fahy M. Impact of
major bleeding and blood transfusions after cardiac surgery : Analysis
from the Acute Catheterization and Urgent Intervention Triage strategY
(ACUITY) trial. Am Heart J . 2012;163(3):522-529.
8. Fröjd V, Jeppsson A. Reexploration for Bleeding and Its Association
With Mortality After Cardiac Surgery. Ann Thorac Surg .
2016;102(1):109-117.
9. Mehta R, Sheng S, O’Brien S, Grover F, Gammie J, Ferguson T, et al.
Reoperation for bleeding in patients undergoing coronary artery bypass
surgery: incidence, risk factors, time trends, and outcomes. Circ
Cardiovasc Qual Outcomes . 2009;2(6):583-590.
10. Schumer EM, Chaney JH, Trivedi JR, Linsky PL, Williams ML, Slaughter
MS. Emergency Coronary Artery Bypass Grafting: Texas Hear Inst J .
2016;43(3):214-219.
11. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M,
et al. AHA Statistical Update Heart Disease and Stroke Statistics —
2016 Update A Report From the American Heart Association.Circulation . 2016;133:38-360.
12. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in
Ambulatory Oral Anticoagulant Use. Am J Med .
2019;128(12):1300-1305.e2.
13. Glotzer T, Hellkamp A, Zimmerman J, Sweeney M, Yee R, Marinchak R.
Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict
Death and Stroke. Circulation . 2003;107:1614-1619.
14. Eikelboom J, Oldgren J, Ph D, Parekh A, Pogue J, Sc M, et al.
Dabigatran versus warfarin in patients with atrial fibrillation. N
Engl J Med . 2009;361(12):1139-1151.
15. Hylek EM, Hanna M, Al-khalidi HR, Ph D, Ansell J, Atar D, et al.
Apixaban versus Warfarin in Patients with Atrial Fibrillation. N
Engl J Med . 2011;365(11):981-992.
16. Kearon C, Akl EA. Antithrombotic Therapy for VTE Disease : CHEST
Guideline and Expert Panel Report Duration of Anticoagulant Therapy Role
of Inferior Vena Cava Filter in Addition to Anticoagulation for Acute
DVT or PE Compression Stocking to Prevent PTS Treatment of Acute.Chest . 2016;149(2):315-352.
17. Wallentin L, Becker R, A B, CP C. Ticagrelor versus clopidegrol in
patients with acute coronary syndrome. N Engl J Med .
2009;361:1045-1057.
18. Shih AW, Crowther MA. Reversal of direct oral anticoagulants: a
practical approach. Hematol Am Soc Hematol Educ Progr .
2016;2(1):612-619.
19. Scaglione F. New Oral Anticoagulants: Comparative Pharmacology with
Vitamin K Antagonists. Clin Pharmacokinet . 2013;52(2):69-82.
20. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg
E, et al. Evaluation of coagulation assays versus LC-MS / MS for
determinations of dabigatran concentrations in plasma. Eur J Clin
Pharmacol . 2013;69(11):1875-1881.
21. Favaloro E, Bonar R, Butler J, Marsden K. Laboratory testing for the
new oral anticoagulants: a review of current practice. Pathology .
2013;45(4):435-437.
22. Reilly P, Lehr T, Haertter S, Connolly S, Yusuf S, Eikelboom J, et
al. The Effect of Dabigatran Plasma Concentrations and Patient
Characteristics on the Frequency of Ischemic Stroke and Major Bleeding
in Atrial Fibrillation Patients: the RE-LY Trial (Randomized Evaluation
of Long-Term Anticoagulation Therapy). J Am Coll Cardiol .
2014;63(4):321-328.
23. Nowak G. The ecarin clotting time, a universal method to quantify
direct thrombin inhibitors. Pathophysiol Haemost Thromb .
2003;33(4):173-183.
24. Samuelson BT, Cuker A. Blood Reviews Measurement and reversal of the
direct oral anticoagulants. Blood Rev . 2019;31(1):77-84.
25. Ghadimi K, Welsby IJ. Reversal of anticoagulation and management of
bleeding after cardiopulmonary bypass - UpToDate. uptodate .
Published online 2019.
26. Tomaselli G, Mahaffey K, Cuker A, Dobesh P, Doherty J, Eikeilboom J.
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in
Patients on Oral Anticoagulants. J Am Coll Cardiol .
2017;70(24):3042-3067.
27. Levy JH. Discontinuation and management of direct-acting
anticoagulants for. Am J Emerg Med . 2019;34(11):14-18.
28. Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, et
al. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa
Inhibitors : A Prospective Cohort Study. Thromb Haemost .
2018;118:842-851.
29. Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Cott EM Van, et
al. Reversal of direct oral anticoagulants: Guidance from the
Anticoagulation Forum. Am J Hematol . 2019;94(6):697-709.
30. Goldstein JN, Refaai MA, Jr TJM, Lewis B, Goldberg-alberts R, Hug
BA, et al. Four-factor prothrombin complex concentrate versus plasma for
rapid vitamin K antagonist reversal in patients needing urgent surgical
or invasive interventions : a phase 3b , open-label , non-inferiority ,
randomised trial. Lancet . 2015;385(9982):2077-2087.
31. Demeyere R, Gillardin S, Arnout J, Strengers PFW. Comparison of
fresh frozen plasma and prothrombin complex concentrate for the reversal
of oral anticoagulants in patients undergoing cardiopulmonary bypass
surgery: a randomized study. Int J Transfus Med .
2010;99(3):251-260.
32. Pollack C, Reilly P, van Ryn J, Eikelboom J, Glund S, Bernstein R.
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N
Engl J Med . 2017;377(5):431-441.
33. Crespo-leiro MG, Amador RL, Granados L, Barge-caballero SMCDE,
Segovia-cubero J, Rangel-sousa FGD, et al. Use of Idarucizumab to
reverse the anticoagulant effect of dabigatran in cardiac transplant
surgery . A multicentric experience in Spain. Clin Transpl .
2019;33(12):e13748.
34. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT,
Lawrence JH, et al. Full study report of andexanet alfa for bleeding
associated with factor Xa inhibitors. N Engl J Med .
2019;380(14):1326-1335.
35. Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha
PK, He L, et al. Pharmacokinetics, safety, and tolerability of edoxaban
in end-stage renal disease subjects undergoing haemodialysis.Thromb Haemost . 2015;113(4):719-727.
36. Awtry E, Loscalzo J. Aspirin. Circulation .
2000;101(10):1206-1218.
37. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et
al. Stopping vs. continuing aspirin before coronary artery surgery.N Engl J Med . 2016;374(8):728-737.
38. Jacob M, Smedira N, Blackstone E, Williams S, Cho L. Effect of
timing of chronic preoperative aspirin discontinuation on morbidity and
mortality in coronary artery bypass surgery. Circulation .
2011;123(6):577-583.
39. Hansson EC, Malm CJ, Hesse C, Björn Hornestam, Dellborg M, Rexius H,
et al. Platelet function recovery after ticagrelor withdrawal in
patients awaiting urgent coronary surgery. Eur J Cardio-thoracic
Surg . 2017;51(4):633-637.
40. Hassan K, Kannmacher J, Wohlmuth P, Budde U, Schmoeckel M, Geidel S.
Cytosorb Adsorption During Emergency Cardiac Operations in Patients at
High Risk of Bleeding. Ann Thorac Surg . 2019;108(1):45-51.
41. Ranucci M, Bozzetti G, Ditta A, Cotza M, Carboni G, Ballotta A, et
al. Surgical Reexploration After Cardiac Operations : Why a Worse
Outcome ? Ann Thorac Surg . 2008;86(5):1557-1562.
42. Biancari F, Airaksinen KEJ, Lip GYH. Benefits and risks of using
clopidogrel before coronary artery bypass surgery: Systematic review and
meta-analysis of randomized trials and observational studies. J
Thorac Cardiovasc Surg . 2012;143(3):665-675.e4.
43. Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MKC,
et al. Clopidogrel administration prior to coronary artery bypass
grafting surgery: The cardiologist’s panacea or the surgeon’s headache?Eur Heart J . 2005;26(6):576-583.
44. Mannacio V, Meier P, Antignano A, Di Tommaso L, De Amicis V, Vosa C.
Individualized strategy for clopidogrel suspension in patients
undergoing off-pump coronary surgery for acute coronary syndrome: A
case-control study. J Thorac Cardiovasc Surg .
2014;148(4):1299-1306.
45. Tanaka KA, Mazzeffi MA, Strauss ER, Szlam F, Guzzetta NA.
Computational simulation and comparison of prothrombin complex
concentrate dosing schemes for warfarin reversal in cardiac surgery.J Anesth . 2016;30(3):369-376.
46. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et
al. 2011 Update to The Society of Thoracic Surgeons and the Society of
Cardiovascular Anesthesiologists Blood Conservation Clinical Practice
Guidelines * The Society of Thoracic Surgeons Blood Conservat. Ann
Thorac Surg . 2011;91(3):944-982.
47. Valeri C, Khabbaz K, Sf K, Marquardt C, Ragno G, Feingold H, et al.
Effect of skin temperature on platelet function in patients undergoing
extracorporeal bypass. J Thorac Cardiovasc Surg .
1992;104(1):108-116.
48. Despotis GJ, Avidan MS, Hogue CW. Mechanisms and Attenuation of
Hemostatic Activation During Extracorporeal Circulation. Ann
Thorac Surg . 2001;72(5):S1821-31.
49. Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman M V,
Jamieson DG, et al. Efficacy of prothrombin complex concentrates for the
emergency reversal of dabigatran-induced anticoagulation. Crit
Care . 2016;20:115.